[go: up one dir, main page]

ATE244018T1 - Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer - Google Patents

Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer

Info

Publication number
ATE244018T1
ATE244018T1 AT96903108T AT96903108T ATE244018T1 AT E244018 T1 ATE244018 T1 AT E244018T1 AT 96903108 T AT96903108 T AT 96903108T AT 96903108 T AT96903108 T AT 96903108T AT E244018 T1 ATE244018 T1 AT E244018T1
Authority
AT
Austria
Prior art keywords
treatment
alzheimer
disease
receptor ligand
aalpha5
Prior art date
Application number
AT96903108T
Other languages
English (en)
Inventor
Gerard Raphael Dawson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE244018T1 publication Critical patent/ATE244018T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406Neurotransmitters
    • G01N33/9426GABA, i.e. gamma-amino-butyrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT96903108T 1995-02-23 1996-02-20 Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer ATE244018T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9503601.8A GB9503601D0 (en) 1995-02-23 1995-02-23 Method of treatment and method of manufacture of medicament
PCT/GB1996/000377 WO1996025948A1 (en) 1995-02-23 1996-02-20 PREPARATION AND USE OF A SPECIFIC GABA-Aα5 RECEPTOR LIGAND FOR TREATMENT OF ALZHEIMER'S DISEASE

Publications (1)

Publication Number Publication Date
ATE244018T1 true ATE244018T1 (de) 2003-07-15

Family

ID=10770108

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96903108T ATE244018T1 (de) 1995-02-23 1996-02-20 Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer

Country Status (10)

Country Link
US (2) US6426343B1 (de)
EP (1) EP0810879B1 (de)
JP (1) JPH11501302A (de)
AT (1) ATE244018T1 (de)
AU (1) AU706515B2 (de)
CA (1) CA2212058C (de)
DE (1) DE69628912T2 (de)
ES (1) ES2201169T3 (de)
GB (1) GB9503601D0 (de)
WO (1) WO1996025948A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU732455C (en) 1997-05-08 2002-09-05 Merck Sharp & Dohme Limited Substituted 1,2,4-triazolo{3,4-a}phthalazine derivatives as gaba alpha 5 ligands
GB9716344D0 (en) * 1997-08-01 1997-10-08 Merck Sharp & Dohme Therapeutic compounds
US6448249B1 (en) 1998-02-25 2002-09-10 Merck Sharp & Dohme Ltd. Substituted 1,2,4-triazolo[3,4-A]phthalazine derivatives as GABAα5 ligands
GB9805557D0 (en) * 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
GB9805559D0 (en) * 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
GB9805561D0 (en) * 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents
JP2002529406A (ja) * 1998-11-12 2002-09-10 メルク エンド カムパニー インコーポレーテッド GABAAα5逆活性薬と、COX−2阻害剤、NSAID、エストロゲン、又はビタミンEとの組合わせ
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
EP1129094A2 (de) 1998-11-12 2001-09-05 Merck & Co., Inc. Therapeutische polymorphe von inverse agonisten des gaba-a alpha-5 rezeptor und pamoat-formulierungen
US6737242B1 (en) 1999-05-07 2004-05-18 Neurogen Corporation Methods for screening GABA-modulatory compounds for specified pharmacological activities
EP1177445B1 (de) * 1999-05-07 2007-07-11 Neurogen Corporation Screening-verfahren von gaba-modulierenden verbindungen für bestimmte pharmakologische wirkungen
GB9911803D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911802D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911804D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
GB0028583D0 (en) 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
US20040023952A1 (en) * 2001-06-20 2004-02-05 Leventhal Audie G. Enhanced brain function by gaba-ergic stimulation
GB0128499D0 (en) * 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
EP1928437A2 (de) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese mittels muscarinrezeptormodulation
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス,インコーポレイティド 神経発生のgaba受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (de) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP3050562A1 (de) 2006-05-22 2016-08-03 The Board of Trustees of the Leland Stanford Junior University Pharmakologische behandlung einer kognitiven beeinträchtigung verwendent einen gabaa rezeptor antagonist
EP2068872A1 (de) 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2298296A1 (de) 2009-08-25 2011-03-23 CNRS Centre National De La Recherche Scientifique Zusammensetzung und Behandlung kognitiver Beeinträchtigungen bei Personen mit Down-Syndrom
US8946206B2 (en) 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
WO2012114342A1 (en) 2011-02-23 2012-08-30 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
KR101743960B1 (ko) * 2015-07-06 2017-06-08 서울대학교산학협력단 G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587802B2 (en) 1985-03-08 1989-08-31 Ferrosan A/S Novel oxadiazolyl imidazobenzodiazepine derivatives and methods of preparing such compounds
FR2672602B1 (fr) 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5182290A (en) 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
ATE170921T1 (de) * 1992-12-10 1998-09-15 Merck Sharp & Dohme Stabil transfizierte zelllinien welche gaba-a rezeptoren exprimieren

Also Published As

Publication number Publication date
DE69628912D1 (de) 2003-08-07
AU706515B2 (en) 1999-06-17
GB9503601D0 (en) 1995-04-12
JPH11501302A (ja) 1999-02-02
DE69628912T2 (de) 2004-06-03
CA2212058A1 (en) 1996-08-29
EP0810879B1 (de) 2003-07-02
US6426343B1 (en) 2002-07-30
AU4725796A (en) 1996-09-11
US6323198B1 (en) 2001-11-27
ES2201169T3 (es) 2004-03-16
EP0810879A1 (de) 1997-12-10
WO1996025948A1 (en) 1996-08-29
CA2212058C (en) 2008-05-13

Similar Documents

Publication Publication Date Title
ATE244018T1 (de) Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer
DE59600309D1 (de) Vorrichtung zur Behandlung von Flüssigkeiten, insbesondere von Blut
DE69525473D1 (de) Vorrichtung zur behandlung von blutgefässen
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
DE69609868D1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
GR3033138T3 (en) Process and compounds for the magnetorelaxometric detection of analytes and use thereof
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
ATE280783T1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE69804659D1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69509843D1 (de) Apparat zur Behandlung z.B. von Poststücken
DE69013880D1 (de) Verfahren und Vorrichtung zur Behandlung von Absorptionssuspensionen, die Flugasche beinhalten.
DE69003009D1 (de) Verfahren zur Behandlung von Fasermaterialien.
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE59101232D1 (de) Verfahren und Mittel zur Herstellung von Bohrungen.
DE69612564D1 (de) Verfahren zur thermischen behandlung von nicht-gasförmigem material
DE3781923D1 (de) Verfahren und vorrichtung zur herstellung von heissem eisenschwamm.
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
DE59008012D1 (de) Mittel zur Behandlung von Leder und Pelzen.
DE69517191D1 (de) Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
DE59607664D1 (de) Verfahren zur Herstellung von 2,4,4,7-Tetramethyl-oct-6-en-3-on und dessen Verwendung als Riechstoff

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties